Skip to content
Open access · CC0 via OpenAlex

Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop

Sara Espinoza, Sundeep Khosla, Joseph A. Baur, Rafael de Cabo, Nicolas Musi

The Journals of Gerontology Series A · 2023 · ▲ 28 citations

Abstract

The geroscience hypothesis posits that by targeting key telomere(definition) attrition, cellular senescence(definition))." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">hallmarks of aging(definition) we may simultaneously prevent or delay several age-related diseases and thereby increase healthspan(definition), or life span spent free of significant disease and disability. Studies are underway to examine several possible pharmacological interventions for this purpose. As part of a National Institute on Aging workshop on the development of function-promoting therapies, scientific content experts provided literature reviews and state-of-the-field assessments for the studies of senolytics(definition), nicotinamide adenine dinucleotide (NAD+) boosters, and metformin. Cellular senescence increases with age, and preclinical studies demonstrate that the use of senolytic drugs improves healthspan in rodents. Human studies using senolytics are in progress. NAD+ and its phosphorylated form, NADP+, play vital roles in metabolism and cellular signaling. Increasing NAD+ by supplementation with precursors including nicotinamide riboside and nicotinamide mononucleotide appears to extend healthspan in model organisms, but human studies are limited and results are mixed. Metformin is a biguanide widely used for glucose lowering, which is believed to have pleiotropic effects targeting several hallmarks of aging. Preclinical studies suggest it improves life span and healthspan, and observational studies suggest benefits for the prevention of several age-related diseases. Clinical trials are underway to examine metformin for healthspan and frailty prevention. Preclinical and emerging clinical studies suggest there is potential to improve healthspan through the use of pharmacologic agents reviewed. However, much further research is needed to demonstrate benefits and general safety for wider use, the appropriate target populations, and longer-term outcomes.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1093/gerona/glad034
Canonical
link ↗
Fetched
2026-06-13 MST

Cite this

APA
Espinoza, S., Khosla, S., Baur, J.A., Cabo, R.D., &amp; Musi, N. (2023). Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop. <em>The Journals of Gerontology Series A</em>. https://doi.org/10.1093/gerona/glad034
Vancouver
Espinoza S, Khosla S, Baur JA, Cabo RD, Musi N. Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop. The Journals of Gerontology Series A. 2023. doi:10.1093/gerona/glad034.
BibTeX
@article{sara2023DrugsT, title = {Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop}, author = {Sara Espinoza and Sundeep Khosla and Joseph A. Baur and Rafael de Cabo and Nicolas Musi}, journal = {The Journals of Gerontology Series A}, year = {2023}, doi = {10.1093/gerona/glad034}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings